KR102457366B1 - Lactobacillus plantarum wikim0127 strain derived from jeju pickled cabbage food and method for preparing composition using same - Google Patents
Lactobacillus plantarum wikim0127 strain derived from jeju pickled cabbage food and method for preparing composition using same Download PDFInfo
- Publication number
- KR102457366B1 KR102457366B1 KR1020210129717A KR20210129717A KR102457366B1 KR 102457366 B1 KR102457366 B1 KR 102457366B1 KR 1020210129717 A KR1020210129717 A KR 1020210129717A KR 20210129717 A KR20210129717 A KR 20210129717A KR 102457366 B1 KR102457366 B1 KR 102457366B1
- Authority
- KR
- South Korea
- Prior art keywords
- wikim0127
- lactobacillus plantarum
- escherichia coli
- present
- composition
- Prior art date
Links
- 240000006024 Lactobacillus plantarum Species 0.000 title claims abstract description 100
- 235000013965 Lactobacillus plantarum Nutrition 0.000 title claims abstract description 100
- 229940072205 lactobacillus plantarum Drugs 0.000 title claims abstract description 100
- 239000000203 mixture Substances 0.000 title claims abstract description 60
- 235000013305 food Nutrition 0.000 title claims abstract description 28
- 238000000034 method Methods 0.000 title claims description 11
- 235000021574 pickled cabbage Nutrition 0.000 title description 6
- 239000006166 lysate Substances 0.000 claims abstract description 26
- 239000000284 extract Substances 0.000 claims abstract description 22
- 239000004480 active ingredient Substances 0.000 claims abstract description 20
- 230000003110 anti-inflammatory effect Effects 0.000 claims abstract description 15
- 239000002537 cosmetic Substances 0.000 claims abstract description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 12
- 238000002360 preparation method Methods 0.000 claims abstract description 8
- 230000000844 anti-bacterial effect Effects 0.000 claims description 34
- 241000894006 Bacteria Species 0.000 claims description 33
- 241000588724 Escherichia coli Species 0.000 claims description 25
- 208000027866 inflammatory disease Diseases 0.000 claims description 24
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 claims description 17
- -1 patch Substances 0.000 claims description 11
- 238000009472 formulation Methods 0.000 claims description 9
- 201000010099 disease Diseases 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 239000006210 lotion Substances 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- 208000004232 Enteritis Diseases 0.000 claims description 5
- 206010016952 Food poisoning Diseases 0.000 claims description 5
- 208000019331 Foodborne disease Diseases 0.000 claims description 5
- 239000006071 cream Substances 0.000 claims description 5
- 239000000499 gel Substances 0.000 claims description 5
- 206010040047 Sepsis Diseases 0.000 claims description 4
- 239000003708 ampul Substances 0.000 claims description 3
- 239000003599 detergent Substances 0.000 claims description 3
- 239000000686 essence Substances 0.000 claims description 3
- 239000002674 ointment Substances 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 239000000344 soap Substances 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims description 2
- 239000003674 animal food additive Substances 0.000 abstract description 16
- 239000007858 starting material Substances 0.000 abstract description 4
- 241000186660 Lactobacillus Species 0.000 abstract description 3
- 229940039696 lactobacillus Drugs 0.000 abstract description 3
- 235000004221 Brassica oleracea var gemmifera Nutrition 0.000 abstract 1
- 244000308368 Brassica oleracea var. gemmifera Species 0.000 abstract 1
- 230000000845 anti-microbial effect Effects 0.000 abstract 1
- 239000004599 antimicrobial Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 208000028774 intestinal disease Diseases 0.000 abstract 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 36
- 239000006228 supernatant Substances 0.000 description 27
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 22
- 230000002401 inhibitory effect Effects 0.000 description 20
- 239000004310 lactic acid Substances 0.000 description 18
- 235000014655 lactic acid Nutrition 0.000 description 18
- 210000004027 cell Anatomy 0.000 description 15
- 241000186427 Cutibacterium acnes Species 0.000 description 13
- 230000009036 growth inhibition Effects 0.000 description 12
- 241000191967 Staphylococcus aureus Species 0.000 description 10
- 238000011156 evaluation Methods 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- 229940055019 propionibacterium acne Drugs 0.000 description 9
- 239000000243 solution Substances 0.000 description 7
- 208000002874 Acne Vulgaris Diseases 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 206010000496 acne Diseases 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 108020004465 16S ribosomal RNA Proteins 0.000 description 5
- 239000003242 anti bacterial agent Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- 235000013355 food flavoring agent Nutrition 0.000 description 5
- 230000001939 inductive effect Effects 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 235000000346 sugar Nutrition 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 4
- 201000004624 Dermatitis Diseases 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- FUWUEFKEXZQKKA-UHFFFAOYSA-N beta-thujaplicin Chemical compound CC(C)C=1C=CC=C(O)C(=O)C=1 FUWUEFKEXZQKKA-UHFFFAOYSA-N 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 238000000855 fermentation Methods 0.000 description 4
- 230000004151 fermentation Effects 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 208000020154 Acnes Diseases 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 241000186429 Propionibacterium Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 239000007884 disintegrant Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 244000144977 poultry Species 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 240000007124 Brassica oleracea Species 0.000 description 2
- 235000003899 Brassica oleracea var acephala Nutrition 0.000 description 2
- 235000011301 Brassica oleracea var capitata Nutrition 0.000 description 2
- 235000001169 Brassica oleracea var oleracea Nutrition 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 206010016936 Folliculitis Diseases 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 238000003794 Gram staining Methods 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 239000004909 Moisturizer Substances 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- IPQKDIRUZHOIOM-UHFFFAOYSA-N Oroxin A Natural products OC1C(O)C(O)C(CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IPQKDIRUZHOIOM-UHFFFAOYSA-N 0.000 description 2
- 241000286209 Phasianidae Species 0.000 description 2
- 229920000388 Polyphosphate Polymers 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 241000607142 Salmonella Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- TUFYVOCKVJOUIR-UHFFFAOYSA-N alpha-Thujaplicin Natural products CC(C)C=1C=CC=CC(=O)C=1O TUFYVOCKVJOUIR-UHFFFAOYSA-N 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000012752 auxiliary agent Substances 0.000 description 2
- IKIIZLYTISPENI-ZFORQUDYSA-N baicalin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IKIIZLYTISPENI-ZFORQUDYSA-N 0.000 description 2
- 229960003321 baicalin Drugs 0.000 description 2
- AQHDANHUMGXSJZ-UHFFFAOYSA-N baicalin Natural products OC1C(O)C(C(O)CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 AQHDANHUMGXSJZ-UHFFFAOYSA-N 0.000 description 2
- 238000002869 basic local alignment search tool Methods 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 235000013376 functional food Nutrition 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000001630 malic acid Substances 0.000 description 2
- 235000011090 malic acid Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000001333 moisturizer Effects 0.000 description 2
- 150000007523 nucleic acids Chemical group 0.000 description 2
- 239000001205 polyphosphate Substances 0.000 description 2
- 235000011176 polyphosphates Nutrition 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- 229930007845 β-thujaplicin Natural products 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- NSMXQKNUPPXBRG-SECBINFHSA-N (R)-lisofylline Chemical compound O=C1N(CCCC[C@H](O)C)C(=O)N(C)C2=C1N(C)C=N2 NSMXQKNUPPXBRG-SECBINFHSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- QJZYHAIUNVAGQP-UHFFFAOYSA-N 3-nitrobicyclo[2.2.1]hept-5-ene-2,3-dicarboxylic acid Chemical compound C1C2C=CC1C(C(=O)O)C2(C(O)=O)[N+]([O-])=O QJZYHAIUNVAGQP-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000272525 Anas platyrhynchos Species 0.000 description 1
- 241000272517 Anseriformes Species 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 235000007319 Avena orientalis Nutrition 0.000 description 1
- 244000075850 Avena orientalis Species 0.000 description 1
- 241000304886 Bacilli Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 1
- 239000005996 Blood meal Substances 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 244000301850 Cupressus sempervirens Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 235000019733 Fish meal Nutrition 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 244000020551 Helianthus annuus Species 0.000 description 1
- 235000003222 Helianthus annuus Nutrition 0.000 description 1
- 240000005979 Hordeum vulgare Species 0.000 description 1
- 235000007340 Hordeum vulgare Nutrition 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 241000218378 Magnolia Species 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 206010034972 Photosensitivity reaction Diseases 0.000 description 1
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 description 1
- 108010064851 Plant Proteins Proteins 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- 241000277331 Salmonidae Species 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
- 239000004902 Softening Agent Substances 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 208000035472 Zoonoses Diseases 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- 239000006053 animal diet Substances 0.000 description 1
- 235000021120 animal protein Nutrition 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- 235000012216 bentonite Nutrition 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 229940036811 bone meal Drugs 0.000 description 1
- 239000002374 bone meal Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940045110 chitosan Drugs 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 235000015140 cultured milk Nutrition 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 206010014665 endocarditis Diseases 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000004467 fishmeal Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 235000020510 functional beverage Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229940107702 grapefruit seed extract Drugs 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 235000020688 green tea extract Nutrition 0.000 description 1
- 229940094952 green tea extract Drugs 0.000 description 1
- 239000007952 growth promoter Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000004021 humic acid Substances 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000036211 photosensitivity Effects 0.000 description 1
- 235000002949 phytic acid Nutrition 0.000 description 1
- 239000000467 phytic acid Substances 0.000 description 1
- 229940068041 phytic acid Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 235000021118 plant-derived protein Nutrition 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 235000008476 powdered milk Nutrition 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000007692 rcm medium Substances 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 229940092258 rosemary extract Drugs 0.000 description 1
- 235000020748 rosemary extract Nutrition 0.000 description 1
- 239000001233 rosmarinus officinalis l. extract Substances 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000010421 standard material Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 206010048282 zoonosis Diseases 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
- 229930195724 β-lactose Natural products 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/324—Foods, ingredients or supplements having a functional effect on health having an effect on the immune system
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Dermatology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Birds (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Biotechnology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
본 발명은 신규한 락토바실러스 플란타룸 균주 및 이를 포함하는 항균 또는 항염용 조성물에 관한 것이다.The present invention relates to a novel Lactobacillus plantarum strain and an antibacterial or anti-inflammatory composition comprising the same.
피부 염증의 원인은 피부 염증의 종류에 따라 다양하지만, 예를 들어, 여드름은 피부 염증을 유발하는 균(bacteria)에 의해 발생한다. 이와 같이 균에 의한 여드름을 치료하기 위해서는 에리스로마이신(erythromycin), 테트라사이클린(tetracycline) 또는 신다마이신(cindamycine)과 같은 항생제를 사용하여 치료한다.The causes of skin inflammation vary depending on the type of skin inflammation, but acne, for example, is caused by bacteria that cause skin inflammation. As such, in order to treat acne caused by bacteria, antibiotics such as erythromycin, tetracycline, or cindamycine are used for treatment.
그러나 이러한 항생제는 장기간 사용시 여드름균 및 기타 상재균에 대하여 내성균을 유발시켜 치료효과를 감소시키고, 광과민작용 등의 부작용을 일으키는 등의 문제를 유발하는 것으로 보고되고 있다. However, these antibiotics are reported to cause problems such as reducing the therapeutic effect by inducing bacteria resistant to acne bacteria and other common flora when used for a long period of time, and causing side effects such as photosensitivity.
또한, 합성 항균제로서 사용되는 파라옥시안식향산에스텔 및 파라벤류 등의 방부제는 피부에 알러지 또 는 부종을 유발하는 부작용이 보고되고 있다(비특허문헌 1). 천연항균제로서, 예를 들어, 히노 키티올 (hinokitiol, 편백추출물), 바이칼린 (baicalin, 황금추출물), 메그노놀 (megnonol, 목련 추출물), 및 자몽종자추출물인 DF-100 등이 상용화되어 있다. 이러한 천연항균제는 pH 또는 킬레이트에 의한 항균효과를 갖는 것으로 보고된 바 있다(비특허문헌 2).In addition, preservatives such as paraoxybenzoate and parabens used as synthetic antibacterial agents have been reported to have side effects of causing allergies or edema to the skin (Non-Patent Document 1). As natural antibacterial agents, for example, hinokitiol (hinokitiol, cypress extract), baicalin (baicalin, golden extract), megnonol (megnonol, magnolia extract), and grapefruit seed extract, DF-100, are commercially available. It has been reported that these natural antibacterial agents have an antibacterial effect by pH or chelate (Non-Patent Document 2).
이에, 본 발명자들은 여드름을 포함하는 피부 염증 질환을 일으키는 균에 대한 항균 활성 및 항염 활성을 갖는 신규한 유산균을 발견하고자 노력한 결과, 제주산 양배추 절임식품에서 유래한 락토바실러스 플란타룸 유산균이 항균 또는 항염 활성을 보이는 것을 확인하고 본 발명을 완성하였다.Accordingly, the present inventors have tried to discover novel lactic acid bacteria having antibacterial and anti-inflammatory activity against bacteria causing skin inflammatory diseases including acne, and as a result, Lactobacillus plantarum lactic acid bacteria derived from pickled cabbage from Jeju is antibacterial or It was confirmed that it showed anti-inflammatory activity, and the present invention was completed.
본 발명의 목적은 수탁번호 KFCC11873P의 락토바실러스 플란타룸 WiKim0127, 이의 배양물, 이의 파쇄물 또는 이의 추출물을 유효성분으로 포함하는 항균 또는 항염용 조성물을 제공하는 것이다.It is an object of the present invention to provide an antibacterial or anti-inflammatory composition comprising Lactobacillus plantarum WiKim0127 of accession number KFCC11873P, its culture, its lysate, or its extract as an active ingredient.
본 발명의 다른 목적은 락토바실러스 플란타룸 WiKim0127, 이의 배양물, 이의 파쇄물 또는 이의 추출물을 유효성분으로 포함하는 피부 염증 질환의 예방 또는 치료용 약학적 조성물, 및 피부 외용제를 제공하는 것이다.Another object of the present invention is to provide a pharmaceutical composition for preventing or treating skin inflammatory diseases comprising Lactobacillus plantarum WiKim0127, a culture thereof, a lysate thereof or an extract thereof as an active ingredient, and an external preparation for the skin.
본 발명의 또 다른 목적은 락토바실러스 플란타룸 WiKim0127, 이의 배양물, 이의 파쇄물 또는 이의 추출물을 유효성분으로 포함하는 항균 또는 항염용 화장료 조성물, 및 항균용 식품 조성물을 제공하는 것이다.Another object of the present invention is to provide an antibacterial or anti-inflammatory cosmetic composition comprising Lactobacillus plantarum WiKim0127, a culture thereof, a lysate thereof or an extract thereof as an active ingredient, and a food composition for antibacterial.
본 발명의 또 다른 목적은 락토바실러스 플란타룸 WiKim0127, 이의 배양물, 이의 파쇄물 또는 이의 추출물을 유효성분으로 포함하는 정장제 조성물, 발효용 유산균 스타터, 및 사료 또는 사료첨가제 조성물을 제공하는 것이다.Another object of the present invention is to provide a bowel preparation composition comprising Lactobacillus plantarum WiKim0127, a culture thereof, a lysate thereof or an extract thereof as an active ingredient, a lactic acid bacteria starter for fermentation, and a feed or feed additive composition.
이에, 본 발명자들은 절임식품으로부터 피부 항균 또는 항염 효과, 피부 염증 질환의 예방, 개선 또는 치료 효과를 나타내는 유산균 균주를 찾고자 노력한 결과, 신규한 락토바실러스 속 유산균 균주인 락토바실러스 플란타룸 WiKim0127(Lactobacillus plantarum WiKim0127)을 분리, 동정하여 본 발명을 완성하게 되었다.Accordingly, the present inventors tried to find a lactic acid bacteria strain that exhibits antibacterial or anti-inflammatory effects on the skin, prevention, improvement or treatment of skin inflammatory diseases from pickled foods, and as a result, a novel Lactobacillus genus lactic acid bacteria strain Lactobacillus plantarum WiKim0127 WiKim0127) was isolated and identified to complete the present invention.
따라서, 본 발명은 락토바실러스 플란타룸 WiKim0127(Lactobacillus plantarum WiKim0127)을 제공한다.Accordingly, the present invention provides Lactobacillus plantarum WiKim0127 ( Lactobacillus plantarum WiKim0127).
본 발명의 락토바실러스 플란타룸 WiKim0127(Lactobacillus plantarum WiKim0127)은 절임식품인 제주산 양배추 절임식품 유래의 락토바실러스 플란타룸 신규 균주이다. 비록 본 발명에서의 락토바실러스 플란타룸 WiKim0127을 제주산 양배추 절임식품에서 분리, 동정하기는 했으나, 이의 입수 경로가 이에 한정되는 것은 아니다.Lactobacillus plantarum WiKim0127 ( Lactobacillus plantarum WiKim0127) of the present invention is a new strain of Lactobacillus plantarum derived from pickled cabbage from Jeju, which is a pickled food. Although Lactobacillus plantarum WiKim0127 in the present invention was isolated and identified from pickled cabbage from Jeju, its acquisition route is not limited thereto.
본 발명에의 실시예를 통해 분리된 유산균 균주는 미생물의 동정 및 분류를 위한 16S rRNA 염기서열 분석 결과, 서열번호: 1의 핵산서열을 갖는 것으로 나타났다. As a result of 16S rRNA sequencing analysis for the identification and classification of microorganisms, the lactic acid bacteria strain isolated through the Examples of the present invention was found to have the nucleic acid sequence of SEQ ID NO: 1.
따라서, 서열번호: 1의 16S rRNA 염기서열을 갖는 본 발명의 미생물을 락토바실러스 플란타룸 WiKim0127(Lactobacillus plantarum WiKim0127)로 명명하였으며, 한국미생물보존센터에 2020년 10월 15일자로 기탁하였다(수탁번호 KFCC11873P).Therefore, the microorganism of the present invention having the 16S rRNA nucleotide sequence of SEQ ID NO: 1 was named Lactobacillus plantarum WiKim0127 ( Lactobacillus plantarum WiKim0127), and was deposited at the Korea Microbial Conservation Center on October 15, 2020 (Accession No. KFCC11873P).
본 발명의 락토바실러스 플란타룸 WiKim0127은 그람양성균이고 호기적 조건과 혐기적 조건에서 모두 성장이 가능한 통성 혐기성(facultative anaerobe)이며, 포자를 형성하지 않고 운동성이 없으며 세포는 간균의 형태를 취하고 있다. Lactobacillus plantarum WiKim0127 of the present invention is a Gram-positive bacterium, a facultative anaerobe capable of growth under both aerobic and anaerobic conditions, does not form spores, does not have motility, and the cells take the form of bacilli.
일 실시예에 있어서, 본 발명의 락토바실러스 플란타룸 WiKim0127이 피부 염증 질환 유발 균주인 프로피오니박테리움 아크네스(Propionibacterium acnes)에 대해 항균 활성을 나타냄을 확인하기 위해 생육 억제환을 측정하였다. 그 결과, 8 ㎜ 이상의 생육 억제환을 형성하여 높은 생육 억제활성을 보임을 확인하였다.In one embodiment, the Lactobacillus plantarum WiKim0127 of the present invention is a skin inflammatory disease-inducing strain Propionibacterium acnes ( Propionibacterium acnes ), the growth inhibition ring was measured to confirm that it exhibits antibacterial activity. As a result, it was confirmed that a growth inhibitory ring of 8 mm or more was formed to show high growth inhibitory activity.
또한, 일 실시예에 있어서, 본 발명의 락토바실러스 플란타룸 WiKim0127의 피부 염증 질환 유발 균주인 프로피오니박테리움 아크네스(Propionibacterium acnes)에 대한 생육 억제능을 평가하였다. 그 결과, 락토바실러스 플란타룸 WiKim0127 균주의 상등액을 10% 농도로 처리한 경우 46%의 생육 억제능을 보이고, 25% 농도로 상등액을 처리한 경우 100%의 생육 억제능을 보임을 확인하였다.In addition, in one embodiment, the growth inhibitory ability of the Lactobacillus plantarum WiKim0127 of the present invention against Propionibacterium acnes , which is a skin inflammatory disease-inducing strain, was evaluated. As a result, it was confirmed that when the supernatant of the Lactobacillus plantarum WiKim0127 strain was treated at a concentration of 10%, it showed 46% growth inhibitory ability, and when the supernatant was treated at a concentration of 25%, it was confirmed that 100% of the growth inhibitory ability was exhibited.
일 실시예에 있어서, 본 발명의 발명의 락토바실러스 플란타룸 WiKim0127이 피부 염증 유발 균주인 스타필로코커스 아우레우스(Staphylococcus aureus)에 대해 항균 활성을 나타냄을 확인하기 위해 생육 억제환을 측정하였다. 그 결과, 8 ㎜ 이상의 생육 억제환을 형성해 생육 억제활성을 보임을 확인하였다.In one embodiment, the growth inhibition ring was measured to confirm that the Lactobacillus plantarum WiKim0127 of the present invention exhibits antibacterial activity against the skin inflammation-inducing strain, Staphylococcus aureus . As a result, it was confirmed that growth inhibitory activity was formed by forming a growth inhibitory ring of 8 mm or more.
또한, 일 실시예에 있어서, 본 발명의 락토바실러스 플란타룸 WiKim0127의 피부 염증 질환 유발 균주인 스타필로코커스 아우레우스(Staphylococcus aureus)에 대한 생육 억제능을 평가하였다. 그 결과, 락토바실러스 플란타룸 WiKim0127의 상등액을 10%로 처리한 경우 대조군(control) 대비 60.2%의 생존율을 보임을 확인하였다.In addition, in one embodiment, the growth inhibitory ability of Lactobacillus plantarum WiKim0127 of the present invention against Staphylococcus aureus , which is a skin inflammatory disease-inducing strain, was evaluated. As a result, it was confirmed that when the supernatant of Lactobacillus plantarum WiKim0127 was treated with 10%, the survival rate was 60.2% compared to the control.
한편, 한 구체예에 있어서, 본 발명의 락토바실러스 플란타룸 WiKim0127의 소재 활용을 위해 사균체, 배양액(발효물) 및 파쇄물을 제조하였다.On the other hand, in one embodiment, dead cells, culture (fermented) and lysate were prepared for the material utilization of Lactobacillus plantarum WiKim0127 of the present invention.
본 발명에 있어서, 상기 배양액은 발효물과 동일한 의미로 사용될 수 있다.In the present invention, the culture medium may be used in the same meaning as the fermented product.
하기 실시예에서는, 본 발명의 락토바실러스 플란타룸 WiKim0127이 일산화질소(nitric oxide, NO)와 같은 대식세포 유래 전염증성 매개물질의 분비를 효과적으로 저해하는 것을 확인하였다.In the following examples, it was confirmed that Lactobacillus plantarum WiKim0127 of the present invention effectively inhibited the secretion of macrophage-derived proinflammatory mediators such as nitric oxide (NO).
따라서, 본 발명은 락토바실러스 플란타룸 WiKim0127(Lactobacillus plantarum WiKim0127), 이의 배양물, 이의 파쇄물 또는 이의 추출물을 유효성분으로 포함하는 항균 또는 항염용 조성물을 제공한다.Accordingly, the present invention provides an antibacterial or anti-inflammatory composition comprising Lactobacillus plantarum WiKim0127 ( Lactobacillus plantarum WiKim0127), a culture thereof, a lysate thereof, or an extract thereof as an active ingredient.
상기 항균용 조성물은 프로피오니박테리움 아크네스(Propionibacterium acnes), 스타필로코커스 아우레우스(Staphylococcus aureus), 대장균(Escherichia coli) 및 살모넬라 타이피뮤리움(Salmonella typhimurium)으로 이루어진 군으로부터 선택되는 하나 이상의 균에 대해 항균 활성을 가지는 것일 수 있으나, 피부 염증 질환을 일으키는 균이라면 제한되지 않고 적용될 수 있다.The antibacterial composition is Propionibacterium acnes ( Propionibacterium acnes ), Staphylococcus aureus ( Staphylococcus aureus ), Escherichia coli ( Escherichia coli ) and Salmonella typhimurium ( Salmonella typhimurium ) One or more bacteria selected from the group consisting of It may have antibacterial activity against, but it can be applied without limitation as long as it is a bacterium that causes skin inflammatory diseases.
본 발명은 락토바실러스 플란타룸 WiKim0127(Lactobacillus plantarum WiKim0127), 이의 배양물, 이의 파쇄물 또는 이의 추출물을 유효성분으로 포함하는, 피부 염증 질환의 예방 또는 치료용 약학적 조성물을 제공한다.The present invention provides a pharmaceutical composition for preventing or treating skin inflammatory diseases, comprising Lactobacillus plantarum WiKim0127 ( Lactobacillus plantarum WiKim0127), a culture thereof, a lysate thereof, or an extract thereof as an active ingredient.
본 발명에 따른 조성물이 약학적 조성물로 활용될 경우, 본 발명의 약학적 조성물은 상기 락토바실러스 플란타룸 WiKim0127 균주 이외에 약학적으로 적합하고 생리학적으로 허용되는 보조제를 사용하여 제조될 수 있으며, 상기 보조제로는 부형제, 붕해제, 감미제, 결합제, 피복제, 팽창제, 윤활제, 활택제 또는 향미제 등을 사용할 수 있다.When the composition according to the present invention is utilized as a pharmaceutical composition, the pharmaceutical composition of the present invention may be prepared using a pharmaceutically suitable and physiologically acceptable adjuvant other than the Lactobacillus plantarum WiKim0127 strain, As the auxiliary agent, an excipient, a disintegrant, a sweetener, a binder, a coating agent, an expanding agent, a lubricant, a lubricant, or a flavoring agent may be used.
상기 약학적 조성물은 투여를 위해서 상기 기재한 유효성분 이외에 추가로 약학적으로 허용가능한 담체를 1종 이상 포함하여 약학적 조성물로 바람직하게 제제화할 수 있다.The pharmaceutical composition may be preferably formulated as a pharmaceutical composition by including one or more pharmaceutically acceptable carriers in addition to the active ingredients described above for administration.
예를 들어, 정제 또는 캡슐제의 형태로의 제제화를 위해, 유효성분은 에탄올, 글리세롤, 물 등과 같은 경구, 무독성의 약학적으로 허용가능한 불활성 담체와 결합될 수 있다. 또한, 원하거나 필요한 경우, 적합한 결합제, 윤활제, 붕해제 및 발색제 또한 혼합물로 포함될 수 있다. 적합한 결합제는 이에 제한되는 것은 아니나, 녹말, 젤라틴, 글루코스 또는 베타-락토오스와 같은 천연당, 옥수수감미제, 아카시아, 트래커캔스 또는 소듐올레이트와 같은 천연 및 합성검, 소듐 스테아레이트, 마그네슘 스테아레이트, 소듐 벤조에이트, 소듐아세테이트, 소듐 클로라이드등을 포함한다. 붕해제는 이에 제한되는 것은 아니나, 녹말, 메틸셀룰로스, 아가, 벤토니트, 잔탄검 등을 포함한다. 액상 용액으로 제제화되는 조성물에 있어서 허용가능한 약제학적 담체로는, 멸균 및 생체에 적합한 것으로서, 식염수, 멸균수, 링거액, 완충식염수, 알부민 주사 용액, 덱스트로즈 용액, 말토덱스트린 용액, 글리세롤, 에탄올 및 이들 성분 중 1 성분이상을 혼합하여 사용할 수 있으며, 필요에 따라 항산화제, 완충액, 정균제 등 다른 통상의 첨가제를 첨가할 수 있다. 또한 희석제, 분산제, 계면활성제, 결합제 및 윤활제를 부가적으로 첨가하여 수용액, 현탁액, 유탁액 등과 같은 주사용 제형, 환약, 캡슐, 과립 또는 정제로 제제화할 수 있다.For example, for formulation in the form of a tablet or capsule, the active ingredient may be combined with an orally, non-toxic, pharmaceutically acceptable inert carrier such as ethanol, glycerol, water, and the like. In addition, if desired or required, suitable binders, lubricants, disintegrants and color-developers may also be included in the mixture. Suitable binders include, but are not limited to, starch, gelatin, natural sugars such as glucose or beta-lactose, corn sweeteners, natural and synthetic gums such as acacia, tracacanth or sodium oleate, sodium stearate, magnesium stearate, sodium benzoate. ate, sodium acetate, sodium chloride, and the like. Disintegrants include, but are not limited to, starch, methylcellulose, agar, bentonite, xanthan gum, and the like. In the composition formulated as a liquid solution, acceptable pharmaceutical carriers, which are sterile and biocompatible, include saline, sterile water, Ringer's solution, buffered saline, albumin injection solution, dextrose solution, maltodextrin solution, glycerol, ethanol and One or more of these components may be mixed and used, and other conventional additives such as antioxidants, buffers, and bacteriostats may be added as needed. In addition, diluents, dispersants, surfactants, binders and lubricants may be additionally added to form an injectable formulation such as an aqueous solution, suspension, emulsion, etc., pills, capsules, granules or tablets.
나아가 해당 분야의 적절한 방법으로 Remington's Pharmaceutical Science, Mack Publishing Company, Easton PA에 개시되어 있는 방법을 이용하여 각 질환에 따라 또는 성분에 따라 바람직하게 제제화할 수 있다.Furthermore, it can be preferably formulated according to each disease or component using the method disclosed in Remington's Pharmaceutical Science, Mack Publishing Company, Easton PA by an appropriate method in the field.
한편, 본 발명은 락토바실러스 플란타룸 WiKim0127(Lactobacillus plantarum WiKim0127), 이의 배양물, 이의 파쇄물 또는 이의 추출물을 유효성분으로 포함하는, 피부 염증 질환의 예방 또는 치료용 피부 외용제를 제공한다.On the other hand, the present invention provides a skin external preparation for preventing or treating skin inflammatory diseases, comprising Lactobacillus plantarum WiKim0127 ( Lactobacillus plantarum WiKim0127), a culture thereof, a lysate thereof, or an extract thereof as an active ingredient.
상기 외용제 조성물은 인체의 외부에 사용하는 것으로, 제형화 형태에 따라, 연고, 패취, 겔, 크림 또는 분무제 제형일 수 있으나, 외용 요법으로 사용될 수 있는 것이라면 형태에 따라 제한되지 않는다. 예컨대, 연고로 제형화될 경우 피부 온도, pH, 수분량, 지질량 등이 고려되야 하고 바셀린, 파라핀, 플라스틱, 라드, 실리콘, 식물성 오일, 왁스, 라놀린 등의 유지성 기제, 유제성 기제, 수용성 기제 및 현탁성 기제 등으로 제형화할 수 있으며, 산화방지제, 방부제, 보습제, 용해보조제, 연화보보제 등의 첨가제를 포함할 수 있다.The composition for external application is used outside the human body, and may be in the form of an ointment, patch, gel, cream or spray, depending on the dosage form, but is not limited according to the form as long as it can be used for external therapy. For example, when formulated as an ointment, skin temperature, pH, moisture content, lipid content, etc. must be considered, and oily bases such as petrolatum, paraffin, plastics, lard, silicone, vegetable oil, wax, lanolin, etc., emulsifying bases, water-soluble bases and suspending properties It may be formulated as a base, and may contain additives such as antioxidants, preservatives, moisturizers, solubilizers, and softening agents.
본 발명에 있어서, “염증 질환”은 염증을 일으키는 균에 의해 발생되는 염증 질환이라면 제한되지 않으나, 바람직하게는 여드름, 모낭염, 비부비동염, 심내막염, 식중독, 장염 및 패혈증으로 이루어진 군으로부터 선택되는 하나 이상의 질환일 수 있다.In the present invention, the "inflammatory disease" is not limited as long as it is an inflammatory disease caused by bacteria that cause inflammation, but preferably at least one selected from the group consisting of acne, folliculitis, rhinosinusitis, endocarditis, food poisoning, enteritis and sepsis. may be a disease.
또한, 본 발명에 있어서, “피부 염증 질환”은 피부에 염증을 일으키는 균에 의해 발생되는 질환이라면 제한되지 않으나, 바람직하게는 여드름, 모낭염 및 피부 농양으로 이루어진 군으로부터 선택되는 하나 이상의 질환일 수 있다.In addition, in the present invention, "skin inflammatory disease" is not limited as long as it is a disease caused by bacteria that cause inflammation in the skin, but preferably one or more diseases selected from the group consisting of acne, folliculitis and skin abscess. .
본 발명은 락토바실러스 플란타룸 WiKim0127(Lactobacillus plantarum WiKim0127), 이의 배양물, 이의 파쇄물 또는 이의 추출물을 유효성분으로 포함하는 피부 항균 또는 항염용 화장료 조성물을 제공한다.The present invention provides a skin antibacterial or anti-inflammatory cosmetic composition comprising Lactobacillus plantarum WiKim0127 ( Lactobacillus plantarum WiKim0127), a culture thereof, a lysate thereof, or an extract thereof as an active ingredient.
본 발명에 따른 화장료 조성물은 당업계에서 통상적으로 제조되는 어떠한 제형으로도 제조될 수 있다. 예를 들어, 상기 화장료 조성물은 화장수, 에센스, 로션, 크림, 앰플, 팩, 젤, 파우더, 파운데이션, 비누 또는 세정제의 제형을 가질 수 있으나, 이에 제한되는 것은 아니다.The cosmetic composition according to the present invention may be prepared in any formulation conventionally prepared in the art. For example, the cosmetic composition may have a formulation of lotion, essence, lotion, cream, ampoule, pack, gel, powder, foundation, soap or detergent, but is not limited thereto.
본 발명의 화장료 조성물은 통상적인 사용 방법에 따라 사용될 수 있으며, 사용자의 피부 상태 또는 취향에 따라 그 사용횟수를 달리할 수 있다.The cosmetic composition of the present invention can be used according to a conventional method of use, and the number of times of use can be changed according to the skin condition or taste of the user.
또한, 본 발명의 화장료 조성물은 통상의 화장품에 사용가능한 모든 종류의 성분, 예컨대 보습제, 자외선 차단제, 중화제, 점증제, 향료, 방부제, 산화방지제 또는 색소를 추가로 포함할 수 있다.In addition, the cosmetic composition of the present invention may further include all kinds of ingredients usable in conventional cosmetics, such as a moisturizer, a sunscreen, a neutralizer, a thickener, a fragrance, a preservative, an antioxidant, or a colorant.
한편, 본 발명은 락토바실러스 플란타룸 WiKim0127(Lactobacillus plantarum WiKim0127), 이의 배양물, 이의 파쇄물 또는 이의 추출물을 유효성분으로 포함하는 항균용 식품 조성물을 제공한다. 상기 식품 조성물은 건강기능식품 또는 음료, 바 등의 형태를 포함할 수 있다.On the other hand, the present invention provides a food composition for antibacterial comprising Lactobacillus plantarum WiKim0127 ( Lactobacillus plantarum WiKim0127), its culture, its lysate, or its extract as an active ingredient. The food composition may include a form of health functional food or beverage, bar, and the like.
본 발명에 있어서, 상기 균주를 유효성분으로 포함하는 식품 조성물은 발효유 등의 음료를 포함할 수 있다. 이에, 본 발명은 락토바실러스 플란타룸 WiKim0127 또는 이의 배양물로 이루어지는 발효용 유산균 스타터를 제공한다.In the present invention, the food composition containing the strain as an active ingredient may include a beverage such as fermented milk. Accordingly, the present invention provides a lactic acid bacteria starter for fermentation consisting of Lactobacillus plantarum WiKim0127 or a culture thereof.
본 발명에 따른 식품 조성물은 상기 약학적 조성물과 동일한 방식으로 제제화되어 기능성 식품으로 이용하거나, 각종 식품에 첨가할 수 있다. 본 발명의 조성물을 첨가할 수 있는 식품으로는 예를 들어, 음료류, 비타민복합제, 건강보조식품류 등이 있다.The food composition according to the present invention may be formulated in the same manner as the pharmaceutical composition and used as a functional food or added to various foods. Foods to which the composition of the present invention can be added include, for example, beverages, vitamin complexes, and health supplements.
본 발명의 식품 조성물은 식품 제조시에 통상적으로 첨가되는 성분을 포함할 수 있으며, 예를 들어, 단백질, 탄수화물, 지방, 영양소, 조미제 및 향미제를 포함한다. 상술한 탄수화물의 예는 모노사카라이드, 예를 들어, 포도당, 과당 등; 디사카라이드, 예를 들어 말토스, 슈크로스, 올리고당 등; 및 폴리사카라이드, 예를 들어 덱스트린, 사이클로덱스트린 등과 같은 통상적인 당 및 자일리톨, 소르비톨, 에리트리톨 등의 당알콜이다. 향미제로서 천연 향미제 [타우마틴, 스테비아추출물 (예를 들어 레바우디오시드A, 글리시르히진 등]) 및 합성향미제(사카린, 아스파르탐 등)를 사용할 수 있다. 예컨대, 본 발명의 식품 조성물이 드링크제와 음료류로 제조되는 경우에는 구연산, 액상과당, 설탕, 포도당, 초산, 사과산, 과즙, 및 각 종 식물 추출액 등을 추가로 포함시킬 수 있다.The food composition of the present invention may include ingredients commonly added during food production, for example, proteins, carbohydrates, fats, nutrients, seasonings and flavoring agents. Examples of the above-mentioned carbohydrates include monosaccharides such as glucose, fructose and the like; disaccharides such as maltose, sucrose, oligosaccharides and the like; and polysaccharides, for example, conventional sugars such as dextrin, cyclodextrin, and the like, and sugar alcohols such as xylitol, sorbitol, and erythritol. As the flavoring agent, natural flavoring agents [taumatine, stevia extract (eg, rebaudioside A, glycyrrhizin, etc.)) and synthetic flavoring agents (saccharin, aspartame, etc.) can be used. For example, when the food composition of the present invention is prepared as a drink or beverage, citric acid, high fructose, sugar, glucose, acetic acid, malic acid, fruit juice, and various plant extracts may be additionally included.
상기 본 발명에 따른 조성물은 사료첨가제 또는 사료로서 이용될 수 있다.The composition according to the present invention may be used as a feed additive or feed.
사료 첨가제로서 이용될 경우, 상기 조성물은 20 내지 90% 고농축액이거나 분말 또는 과립 형태로 제조될 수 있다. 상기 사료첨가제는 구연산, 후말산, 아디픽산, 젖산, 사과산등의 유기산이나 인산 나트륨, 인산 칼륨, 산성 피로인산염, 폴리인산염(중합인산염) 등의 인산염이나, 폴리페놀, 카테킨, 알파-토코페롤, 로즈마리 추출물, 비타민 C, 녹차 추출물, 감초 추출물, 키토산, 탄닌산, 피틴산 등의 천연 항산화제 중 어느 하나 또는 하나 이상을 추가로 포함할 수 있다. 사료로서 이용될 경우, 상기 조성물은 통상의 사료 형태로 제제화 될 수 있으며, 통상의 사료성분을 함께 포함할 수 있다.When used as a feed additive, the composition may be a high concentration of 20 to 90% or may be prepared in powder or granular form. The feed additives include organic acids such as citric acid, humic acid, adipic acid, lactic acid, and malic acid, phosphates such as sodium phosphate, potassium phosphate, acid pyrophosphate, polyphosphate (polyphosphate), polyphenol, catechin, alpha-tocopherol, rosemary Extract, vitamin C, green tea extract, licorice extract, chitosan, tannic acid, any one or more of natural antioxidants such as phytic acid may be further included. When used as a feed, the composition may be formulated in the form of a conventional feed, and may include common feed ingredients together.
상기 사료첨가제 및 사료는 곡물, 예를 들면 분쇄 또는 파쇄된 밀, 귀리, 보리, 옥수수 및 쌀; 식물성 단백질 사료, 예를 들면 평지, 콩, 및 해바라기를 주성분으로 하는 사료; 동물성 단백질 사료, 예를 들면 혈분, 육분, 골분 및 생선분; 당분 및 유제품, 예를 들면 각종 분유 및 유장 분말로 이루어지는 건조성분 등을 더 포함할 수 있으며, 이외에도 영양보충제, 소화 및 흡수향상제, 성장촉진제 등을 더 포함할 수 있다.The feed additive and feed include grains such as milled or crushed wheat, oats, barley, corn and rice; plant protein feeds, such as feeds based on rape, soybean, and sunflower; animal protein feeds such as blood meal, meat meal, bone meal and fish meal; Sugar and dairy products, for example, may further include dry ingredients made of various powdered milk and whey powder, and may further include nutritional supplements, digestion and absorption enhancers, growth promoters, and the like.
상기 사료첨가제는 동물에게 단독으로 투여하거나 식용 담체 중에서 다른 사료첨가제와 조합하여 투여할 수도 있다. 또한, 상기 사료첨가제는 탑드레싱으로서 또는 이들을 동물사료에 직접 혼합하거나 또는 사료와 별도의 경구제형으로 용이하게 동물에게 투여할 수 있다. 상기 사료첨가제를 동물사료와 별도로 투여할 경우, 당해 기술분야에 잘 알려진 바와 같이 약제학적으로 허용가능한 식용 담체와 조합하여, 즉시 방출 또는 서방성 제형으로 제조할 수 있다. 이러한 식용 담체는 고체 또는 액체, 예를 들어 옥수수전분, 락토오스, 수크로오스, 콩플레이크, 땅콩유, 올리브유, 참깨유 및 프로필렌글리콜일 수 있다. 고체 담체가 사용될 경우, 사료첨가제는 정제, 캡슐제, 산제, 트로키제 또는 함당정제 또는 미분산성 형태의 탑 드레싱일 수 있다. 액체 담체가 사용될 경우, 사료첨가제는 젤라틴 연질 캡슐제, 또는 시럽제나 현탁액, 에멀젼제, 또는 용액제의 제형일 수 있다. The feed additive may be administered alone or in combination with other feed additives in an edible carrier. In addition, the feed additive can be easily administered to the animal as a top dressing, directly mixing them with animal feed, or in an oral formulation separate from the feed. When the feed additive is administered separately from the animal feed, it may be combined with a pharmaceutically acceptable edible carrier as well known in the art to prepare an immediate release or sustained release formulation. Such edible carriers may be solid or liquid, for example cornstarch, lactose, sucrose, soybean flakes, peanut oil, olive oil, sesame oil and propylene glycol. When a solid carrier is used, the feed additive may be a tablet, a capsule, a powder, a troche or a sugar-containing tablet, or a top dressing in a microdispersed form. When a liquid carrier is used, the feed additive may be in the form of a gelatin soft capsule, or a syrup or suspension, emulsion, or solution.
또한, 상기 사료첨가제 및 사료는 보조제, 예를 들어 보존제, 안정화제, 습윤제 또는 유화제, 용액촉진제 등을 함유할 수 있다. 상기 사료첨가제는 침주, 분무 또는 혼합하여 동물의 사료에 첨가하여 이용될 수 있다.In addition, the feed additives and feed may contain auxiliary agents, for example, preservatives, stabilizers, wetting or emulsifying agents, solution accelerators, and the like. The feed additive may be used by adding to animal feed by immersion, spraying, or mixing.
본 발명의 사료 또는 사료첨가제는 포유류, 가금 및 어류를 포함하는 다수의 동물식이에 적용할 수 있다.The feed or feed additive of the present invention can be applied to a number of animal diets including mammals, poultry and fish.
본 발명에 있어서 동물을 포유류를 포함하고 포유류로서 돼지, 소, 양, 염소, 실험용 설치동물, 및 실험용 설치동물뿐만 아니라, 애완동물(예: 개, 고양이) 등에게 사용할 수 있으며, 상기 가금류로서 닭, 칠면조, 오리, 거위, 꿩, 및 메추라기 등에도 사용할 수 있고, 상기 어류로서 송어 등에 이용될 수 있으나, 이에 한정되는 것은 아니다.In the present invention, animals include mammals, and as mammals, pigs, cattle, sheep, goats, laboratory rodents, and laboratory rodents can be used as well as pets (eg, dogs, cats), etc., and the poultry is chicken. , can be used for turkey, duck, geese, pheasant, and quail, and the like, and can be used for trout as the fish, but is not limited thereto.
본 발명에 따른 조성물에 포함되는 락토바실러스 플란타룸 WiKim0127 균주의 양은 1회를 기준으로 약 106 내지 1012 cfu/g일 수 있으며, 예컨대 107 내지 1011 cfu/g, 108 내지 1010 cfu/g일 수 있다. 균주를 투여할 경우에는 생균 상태로 투여하는 것이 바람직하며, 섭취 전에 사멸시키거나 감쇄(attenuation) 상태로 투여할 수 있다. 또한, 배양 상등액 등을 사용하여 제조할 경우에는 열처리 과정을 통한 멸균화 과정을 추가적으로 거칠 수 있다. 최소의 효능을 가지는데 필요한 균주량 및 일일 섭취 정도는 섭취자의 신체 또는 건강상태에 따라 달라질 수 있으나, 일반적으로 약 106 내지 1012 cfu/g일 수 있으며, 예컨대 107 내지 1011 cfu/g, 108 내지 1010 cfu/g일 수 있다.The amount of the Lactobacillus plantarum WiKim0127 strain contained in the composition according to the present invention may be about 10 6 to 10 12 cfu/g based on one time, for example, 10 7 to 10 11 cfu/g, 10 8 to 10 10 cfu/g. When administering the strain, it is preferable to administer it in a live state, and it can be killed or administered in an attenuated state before ingestion. In addition, in the case of manufacturing using a culture supernatant, etc., a sterilization process through a heat treatment process may be additionally performed. The amount of strain required to have the minimum efficacy and the daily intake level may vary depending on the body or health condition of the ingester, but in general, it may be about 10 6 to 10 12 cfu/g, for example, 10 7 to 10 11 cfu/g , 10 8 to 10 10 cfu/g.
또한, 본 발명의 락토바실러스 플란타룸 WiKim0127는, 유산균의 일반적인 정장 효과 및 면역 증강 효과를 갖는다. 락토바실러스 속의 유산균이 정장 효과 및 면역 증강 효과를 갖는다는 것은 잘 알려져 있는 사실이다.In addition, Lactobacillus plantarum WiKim0127 of the present invention has a general intestinal effect and immune enhancing effect of lactic acid bacteria. It is a well-known fact that the lactic acid bacteria of the genus Lactobacillus have an intestinal effect and an immune enhancing effect.
또한, 본 발명에 따른 락토바실러스 플란타룸 WiKim0127은 프로바이오틱스로서 사람 또는 동물의 정장, 면역강화 등의 용도뿐만 아니라 상기 기술한 병원균의 항균을 위한 용도 및 항염 용도로 다양하게 활용될 수 있다.In addition, the Lactobacillus plantarum WiKim0127 according to the present invention can be used in various ways as probiotics for human or animal intestines, immunity enhancement, etc., as well as for antibacterial and anti-inflammatory purposes of the above-described pathogens.
본 발명에 따른 조성물에 포함되는 락토바실러스 플란타룸 WiKim0127은 생균체 또는 사균체로서 존재할 수 있으며, 또한 건조 또는 동결건조된 형태로 존재할 수도 있다. 다양한 조성물 내에 포함시키기 적합한 유산균의 형태 및 제제화 방법은 당업자에게 잘 알려져 있다. 예를 들어, 락토바실러스 플란타룸 WiKim0127 균주는 공지의 액체 배지 또는 고체 배지에서 배양시켜 수득한 배양물 또는 발효물이거나, 상기 균주를 유기용매로 추출한 추출물, 상기 균주의 세포막을 용해시키거나 패쇄 또는 균질화 처리한 용해물(또는 파쇄물) 등의 형태로 제제화될 수 있으나, 이에 제한되지 않는다.Lactobacillus plantarum WiKim0127 included in the composition according to the present invention may exist as a live cell or a dead cell, and may also exist in a dried or lyophilized form. Forms of lactic acid bacteria suitable for inclusion in various compositions and methods of formulation are well known to those skilled in the art. For example, the Lactobacillus plantarum WiKim0127 strain is a culture or fermented product obtained by culturing in a known liquid medium or solid medium, an extract obtained by extracting the strain with an organic solvent, dissolving or blocking the cell membrane of the strain or It may be formulated in the form of a homogenized lysate (or lysate), but is not limited thereto.
일 실시예에 있어서, 본 발명의 락토바실러스 플란타룸 WiKim0127 상등액을 대장균(Escherichia coli) 및 살모넬라 타이피뮤리움(Salmonella typhimurium)에 처리한 결과, 7.6 mm 이상의 생육 억제환을 형성함을 확인한 결과를 확인하였다. 이에 따라 본 발명의 락토바실러스 플란타룸 WiKim0127 균주가 대장균(Escherichia coli) 및 살모넬라 타이피뮤리움(Salmonella typhimurium)에 대해 항균 활성을 나타내고 동시에 이들 균주와 관련된 염증 질환에 대해 효과를 나타냄을 알 수 있다.In one embodiment, the Lactobacillus plantarum WiKim0127 supernatant of the present invention was treated with E. coli ( Escherichia coli ) and Salmonella typhimurium ) As a result, it was confirmed that a growth inhibition ring of 7.6 mm or more was formed. did. Accordingly, it can be seen that the Lactobacillus plantarum WiKim0127 strain of the present invention exhibits antibacterial activity against Escherichia coli and Salmonella typhimurium and at the same time exhibits an effect on inflammatory diseases related to these strains.
본 발명에 있어서, "대장균(Escherichia coli)"은 당업계에서 일반적으로 식중독, 장염 및 패혈증을 유발하는 것으로 알려진 균주를 의미한다. 대장균은 한국 공개특허 제10-2016-0135775호에 따르면 식중독을 일으키고, 한국 등록특허 제10-2204327호에 따르면 패혈증을 일으키며, 한국 공개특허 제10-2002-0032890호에 따르면 장염을 일으키는 것으로 보고된다.In the present invention, "E. coli ( Escherichia coli )" means a strain known in the art to generally cause food poisoning, enteritis and sepsis. E. coli causes food poisoning according to Korean Patent Publication No. 10-2016-0135775, and Korean Patent Registration No. 10-2204327 According to Korean Patent Publication No. 10-2002-0032890, it is reported to cause enteritis.
본 발명에 있어서, “살모넬라 타이피뮤리움(Salmonella typhimurium)”은 사람에게 가장 빈번한 감염을 일으키는 살모넬라 균주로 알려져 있으며, 가금에서뿐만 아니라, 사람에게 감염하여 식중독을 일으킬 수 있는 인수공통 감염 균으로 알려져 있다(한국 등록특허 제10-1151532호 참고). 또한, 살모넬라 균은 장염, 폐렴 및 패혈증의 질환을 일이키는 것으로도 알려져 있다(한국 공개특허 제10-2019-0079850호 참고).In the present invention, " Salmonella typhimurium " is known as the Salmonella strain that causes the most frequent infection in humans, and is known as a zoonotic infection that can cause food poisoning by infecting humans as well as in poultry ( See Korean Patent Registration No. 10-1151532). In addition, Salmonella is also known to cause diseases of enteritis, pneumonia and sepsis (refer to Korean Patent Publication No. 10-2019-0079850).
본 발명의 이점 및 특징, 그리고 그것들을 달성하는 방법은 상세하게 후술되어있는 실시예들을 참조하면 명확해질 것이다. 그러나 본 발명은 이하에서 개시되는 실시예들에 한정되는 것이 아니라 서로 다른 다양한 형태로 구현될 것이며, 단지 본 실시예들은 본 발명의 개시가 완전하도록 하고, 본 발명이 속하는 기술분야에서 통상의 지식을 가진 자에게 발명의 범주를 완전하게 알려주기 위해 제공되는 것이며, 본 발명은 청구항의 범주에 의해 정의될 뿐이다.Advantages and features of the present invention, and methods for achieving them, will become apparent with reference to the embodiments described below in detail. However, the present invention is not limited to the embodiments disclosed below, but will be embodied in various different forms, and only these embodiments allow the disclosure of the present invention to be complete, and common knowledge in the technical field to which the present invention belongs It is provided to fully inform the possessor of the scope of the invention, and the present invention is only defined by the scope of the claims.
본 발명은 제주산 양배추 절임식품에서 유래한 락토바실러스 플란타룸 WiKim0127(Lactobacillus plantarum WiKim0127; 수탁번호 KFCC11873P), 이의 배양물, 이의 파쇄물 또는 이의 추출물을 유효성분으로 포함하는 항균 또는 항염용 조성물에 관한 것이다.The present invention relates to an antibacterial or anti-inflammatory composition comprising, as an active ingredient, Lactobacillus plantarum WiKim0127 ( Lactobacillus plantarum WiKim0127; accession number KFCC11873P), a culture thereof, a lysate thereof, or an extract thereof derived from pickled cabbage from Jeju. .
본 발명에 따른 상기 조성물은 약학적 조성물, 피부 외용제, 화장료 조성물, 식품 조성물, 정장제 조성물, 유산균 스타터 및 사료 또는 사료 첨가제 조성물 등으로 다양하게 활용될 수 있다.The composition according to the present invention can be used in various ways as pharmaceutical compositions, external preparations for skin, cosmetic compositions, food compositions, intestinal preparation compositions, lactic acid bacteria starters and feed or feed additive compositions, and the like.
도 1은 본 발명에 따라 절임식품에서 분리된 11균주의 프로피오니박테리움 아크네스에 대한 항균 활성 평가를 보여준다.
도 2는 본 발명의 락토바실러스 플란타룸 WiKim0127 상등액의 프로피오니박테리움 아크네스에 대한 생육 억제환 결과를 보여준다.
도 3은 본 발명의 락토바실러스 플란타룸 WiKim0127 상등액의 프로피오니박테리움 아크네스에 대한 생육 억제능이 46% 이상을 나타냄을 보여준다.
도 4는 본 발명의 락토바실러스 플란타룸 WiKim0127 상등액을 농도별로 처리했을 때 프로피오니박테리움 아크네스의 생장곡선을 보여준다.
도 5는 본 발명에 따라 절임식품에서 분리된 11균주의 스타필로코커스 아우레우스에 대한 항균 활성 평가를 보여준다.
도 6은 본 발명의 락토바실러스 플란타룸 WiKim0127 상등액의 스타필로코커스 아우레우스에 대한 생육 억제환 결과를 보여준다.
도 7은 본 발명의 락토바실러스 플란타룸 WiKim0127 상등액의 스타필로코커스 아우레우스에 대한 생육 억제능이 39% 이상을 나타냄을 보여준다.
도 8은 본 발명에 따라 제조된 락토바실러스 플란타룸 WiKim0127의 사균체, 발효물 및 파쇄물을 보여준다.
도 9는 본 발명의 락토바실러스 플란타룸 WiKim0127 상등액을 처리한 경우 NO 생성량이 억제되는 것을 보여준다.
도 10은 본 발명의 락토바실러스 플란타룸 WiKim0127 사균체를 처리한 경우 NO 생성량이 억제되는 것을 보여준다.
도 11은 본 발명의 락토바실러스 플란타룸 WiKim0127 상등액을 대장균(Escherichia coli) 및 살모넬라 타이피뮤리움(Salmonella typhimurium)에 처리한 결과, 생육 억제환을 형성함을 확인한 결과를 보여준다. 이에 따라 본 발명의 락토바실러스 플란타룸 WiKim0127 균주가 대장균(Escherichia coli) 및 살모넬라 타이피뮤리움(Salmonella typhimurium)에 대해 항균 활성을 나타내고 동시에 이들 균주와 관련된 염증 질환에 대해 효과를 나타냄을 알 수 있다.1 shows the evaluation of antibacterial activity against Propionibacterium acnes of 11 strains isolated from pickled foods according to the present invention.
Figure 2 shows the growth inhibition ring results for Propionibacterium acnes of the Lactobacillus plantarum WiKim0127 supernatant of the present invention.
3 shows that the Lactobacillus plantarum WiKim0127 supernatant of the present invention exhibits growth inhibitory activity against Propionibacterium acnes of 46% or more.
Figure 4 shows the growth curve of Propionibacterium acnes when the Lactobacillus plantarum WiKim0127 supernatant of the present invention is treated by concentration.
5 shows the evaluation of antibacterial activity against Staphylococcus aureus of 11 strains isolated from pickled foods according to the present invention.
Figure 6 shows the growth inhibition ring results for Staphylococcus aureus of the Lactobacillus plantarum WiKim0127 supernatant of the present invention.
7 shows that the Lactobacillus plantarum WiKim0127 supernatant of the present invention exhibits a growth inhibitory activity against Staphylococcus aureus of 39% or more.
8 shows dead cells, fermented products and lysates of Lactobacillus plantarum WiKim0127 prepared according to the present invention.
9 shows that NO production is suppressed when the Lactobacillus plantarum WiKim0127 supernatant of the present invention is treated.
10 shows that the NO production amount is suppressed when the Lactobacillus plantarum WiKim0127 dead cells of the present invention are treated.
11 shows the results of confirming that the Lactobacillus plantarum WiKim0127 supernatant of the present invention was treated with Escherichia coli and Salmonella typhimurium to form a growth inhibition ring. Accordingly, the Lactobacillus plantarum WiKim0127 strain of the present invention is Escherichia coli ) and Salmonella typhimurium ( Salmonella typhimurium ) It can be seen that it exhibits antibacterial activity and at the same time exhibits an effect on inflammatory diseases associated with these strains.
이하, 본 발명을 실시예를 통해 상세히 설명한다. 하기 실시예는 본 발명을 예시하는 것일 뿐 본 발명의 범위가 하기 실시예에 한정되는 것은 아니다.Hereinafter, the present invention will be described in detail through examples. The following examples only illustrate the present invention, but the scope of the present invention is not limited to the following examples.
[[ 실시예Example ]]
실시예Example 1: One: 락토바실러스Lactobacillus 플란타룸Plantarum WiKim0127의WiKim0127's 동정 Sympathy
종균 발굴을 위해 제주산 양배추로 절임식품을 각각 제조하였다. 제조된 절임식품의 발효 시간별 절임식품 종균을 분리하였다. Each pickled food was prepared with Jeju cabbage for the purpose of discovering the seeds. The pickled food seeds were isolated by fermentation time of the prepared pickled foods.
이를 위해 제주산 양배추로 제조된 절임식품의 발효 시간별 절임식품 파쇄액을 제조하고 이를 희석하여 MRS agar에 배양 후 genomic DNA extraction kit(iNtRON Biotechnology, Korea)를 사용하여 DNA를 추출하였다. 16S rRNA gene을 증폭하기 위하여 추출된 genomic DNA를 template로 하여 27F(5'-AGAGTTTGATCCTGGCTCAG-3', forward), 1492R(5'-GGCTACCTTGTTACGACTT-3', reverse) 프라이머를 이용하여 PCR을 진행하였다. To this end, a lysate of pickled foods for each fermentation time of pickled foods prepared from Jeju cabbage was prepared, diluted and cultured on MRS agar, and DNA was extracted using a genomic DNA extraction kit (iNtRON Biotechnology, Korea). Using the extracted genomic DNA as a template to amplify the 16S rRNA gene, PCR was performed using primers 27F (5'-AGAGTTTGATCCTGGCTCAG-3', forward), 1492R (5'-GGCTACCTTGTTACGACTT-3', reverse).
PCR 조건은 denaturation 95℃ 1분, annealing 45℃ 1분, extension 72℃ 1분 30초로 30 사이클을 수행하였다. 얻어진 PCR 산물은 마크로젠(Seoul, Korea)에 의뢰하여 서열 분석을 진행하였다. 16S rRNA 서열을 National Center for Biotechnology Information(NCBI)의 Basic Local Alignment Search Tool(BLAST)을 이용하여 분석하고 절임식품으로부터 11 균주를 분리 동정하였다.PCR conditions were 30 cycles of denaturation at 95°C for 1 minute, annealing at 45°C for 1 minute, and extension at 72°C for 1 minute and 30 seconds. The PCR product obtained was commissioned to Macrogen (Seoul, Korea) and sequence analysis was performed. The 16S rRNA sequence was analyzed using the Basic Local Alignment Search Tool (BLAST) of the National Center for Biotechnology Information (NCBI), and 11 strains were isolated and identified from pickled foods.
실시예Example 2: 2: 락토바실러스Lactobacillus 플란타룸Plantarum WiKim0127의WiKim0127's 항균 또는 항염 활성 확인 Confirmation of antibacterial or anti-inflammatory activity
-피부 염증 질환 유발 균주 Propionibacterium acnes 에 대한 항균 활성 평가 - Propionibacterium , a strain that causes skin inflammatory diseases Evaluation of antibacterial activity against acnes
피부 염증 질환 유발 균주인 Propionibacterium acnes에 대한 항균 활성 평가를 위해 생육 억제환을 측정하였다. Propionibacterium , a strain that causes skin inflammatory diseases Growth inhibitory rings were measured for the evaluation of antibacterial activity against acnes .
P. acnes를 37℃에서 48시간 배양하고 0.5 McFarland 표준 탁도 농도(1×108 CFU/mL)가 되도록 현탁시켜 stock culture로 사용한다. 1×107 CFU/mL 농도가 되도록 RCM 배지로 10배 희석하고 0.1 mL 분주하여 일회용 spreader로 균일하게 도말하였다. P. acnes is cultured at 37°C for 48 hours and suspended to 0.5 McFarland standard turbidity concentration (1×10 8 CFU/mL) and used as stock culture. It was diluted 10-fold with RCM medium to a concentration of 1×10 7 CFU/mL, and 0.1 mL was dispensed and spread evenly with a disposable spreader.
평판 배지 표면에 각 유산균을 10 μL씩 분주하여 건조한 후 anaerobic jar (anaerojar, Oxoid Ltd)에서 anerobic gas kit (AnaerobegenTM 2.5L, Oxoid)를 이용하여 37℃에서 48시간 혐기 배양하고, 배양 후 각 clear zone (mm)의 직경을 측정하여 항균활성을 평가하였다. After dispensing 10 μL of each lactic acid bacteria on the surface of the plate medium and drying them, anaerobic incubation at 37°C for 48 hours using an anerobic gas kit (AnaerobegenTM 2.5L, Oxoid) in an anaerobic jar (anaerojar, Oxoid Ltd). After culturing, each clear zone The antibacterial activity was evaluated by measuring the diameter of (mm).
상기 실시예 1에서 분리한 유산균 11균주의 상등액을 10배 농축하여 10 μL씩 항균활성 평가에 사용하였다. The supernatant of the 11 strains of lactic acid bacteria isolated in Example 1 was concentrated 10 times and used for the evaluation of antibacterial activity by 10 μL.
그 결과, 락토바실러스 플란타룸 WiKim0127 균주의 상등액을 처리한 경우 11 ㎜ 이상의 생육 억제환을 형성하여 높은 생육 억제활성을 보임을 확인하였다(도 1 및 2).As a result, it was confirmed that when the supernatant of the Lactobacillus plantarum WiKim0127 strain was treated, a growth inhibitory ring of 11 mm or more was formed, thereby showing high growth inhibitory activity ( FIGS. 1 and 2 ).
-피부 염증 질환 유발 균주 Propionibacterium acnes 에 대한 생육 억제능 평가 - Propionibacterium , a strain that causes skin inflammatory diseases Evaluation of growth inhibition ability for acnes
트러블 유발 균주 P. acnes에 대한 생육 저해능을 평가하였다. The growth inhibitory ability against the trouble-causing strain P. acnes was evaluated.
96 well microplate를 사용하여 각 well 당 200 μL를 총량으로 하여 10% 농도로 유산균 상등액을 혼합하여 48시간 배양하고 P. acnes의 생존율을 확인하였다. Using a 96-well microplate, 200 μL per well was mixed with the lactic acid bacteria supernatant at a concentration of 10% and cultured for 48 hours, and the survival rate of P. acnes was confirmed.
유산균 상등액을 배합하지 않은 군을 control로 사용하였다. The group not containing the lactic acid bacteria supernatant was used as a control.
그 결과, 락토바실러스 플란타룸 WiKim0127 균주의 상등액을 10%로 처리한 경우 control 대비 54%의 생존율을 보임을 확인하였다(도 3).As a result, it was confirmed that when the supernatant of the Lactobacillus plantarum WiKim0127 strain was treated with 10%, the survival rate was 54% compared to the control (FIG. 3).
이후, 락토바실러스 플란타룸 WiKim0127 균주의 상등액 처리구에 대한 생장 profile을 분석하였다. Then, the growth profile for the supernatant treatment group of the Lactobacillus plantarum WiKim0127 strain was analyzed.
96 well microplate를 사용하여 각 well 당 200 μL를 총량으로 하여 0%, 10%, 25%의 유산균 상등액을 혼합하여 37℃에서 배양하고 흡광도(OD600)를 측정하여 P. acnes의 생장을 확인하였다. Using a 96-well microplate, the total amount of 200 μL per well was mixed with 0%, 10%, and 25% lactic acid bacteria supernatant, cultured at 37°C, and absorbance (OD 600 ) was measured to confirm the growth of P. acnes . .
그 결과, WiKim0127 균주의 상등액을 10% 농도로 처리한 경우 46%의 생육 억제능을 보이고, 25% 농도로 상등액을 처리한 경우 100%의 생육 억제능을 보임을 확인하였다(도 4).As a result, it was confirmed that when the supernatant of the WiKim0127 strain was treated at a concentration of 10%, it showed 46% growth inhibition, and when the supernatant was treated at a concentration of 25%, it was confirmed that 100% of the growth inhibition ability was shown (FIG. 4).
-피부 염증 질환 유발 균주 Staphylococcus aureus 에 대한 항균활성 평가 - Evaluation of antibacterial activity against the skin inflammatory disease-causing strain Staphylococcus aureus
Staphylococcus aureus에 대한 항균활성 평가를 위해 생육 억제환을 측정하였다. Growth inhibitory rings were measured to evaluate antibacterial activity against Staphylococcus aureus .
S. aureus를 37℃에서 24시간 배양하고 0.5 McFarland 표준 탁도 농도(1×108 CFU/mL)가 되도록 현탁시켜서 stock culture로 사용하였다. 1×107 CFU/mL 농도가 되도록 배지로 10배 희석하고 0.1 mL 분주하여 일회용 spreader로 균일하게 도말하였다. 평판 배지 표면에 각 유산균을 10 μL씩 분주하고 건조한 후 37℃에서 24시간 배양하고, 배양 후 각 clear zone (mm)의 직경을 측정하여 항균 활성을 평가하였다. S. aureus was cultured at 37° C. for 24 hours and suspended to 0.5 McFarland standard turbidity concentration (1×10 8 CFU/mL) and used as stock culture. It was diluted 10-fold with medium to a concentration of 1×10 7 CFU/mL, and 0.1 mL was dispensed and spread evenly with a disposable spreader. 10 μL of each lactic acid bacteria was dispensed on the surface of the plate medium, dried, incubated at 37° C. for 24 hours, and then the diameter of each clear zone (mm) was measured to evaluate the antibacterial activity.
그 결과, 락토바실러스 플란타룸 WiKim0127 균주에서 8 ㎜ 이상의 생육 억제환을 형성해 생육 억제활성을 보임을 확인하였다(도 5 및 6). As a result, it was confirmed that the Lactobacillus plantarum WiKim0127 strain showed growth inhibitory activity by forming a growth inhibitory ring of 8 mm or more ( FIGS. 5 and 6 ).
-피부 염증 질환 유발 균주 Staphylococcus aureus 에 대한 생육 억제능 평가 - Evaluation of the growth inhibition ability of Staphylococcus aureus , a strain causing skin inflammatory disease
균주 S. aureus에 대한 생장저해능을 평가하였다. The growth inhibition ability for the strain S. aureus was evaluated.
96 well microplate를 사용하여 각 well 당 200μL를 총량으로 하여 10% 농도로 락토바실러스 플란타룸 WiKim0127 상등액을 혼합하여 48시간 배양하고 S. aureus의 생장을 확인하였다. Using a 96-well microplate, 200 μL per well was mixed with the Lactobacillus plantarum WiKim0127 supernatant at 10% concentration and cultured for 48 hours, and the growth of S. aureus was confirmed.
락토바실러스 플란타룸 WiKim0127 상등액을 배합하지 않은 군을 control로 사용하였다.Lactobacillus plantarum WiKim0127 The group not containing the supernatant was used as a control.
그 결과, 락토바실러스 플란타룸 WiKim0127의 상등액을 10%로 처리한 경우 control 대비 60.2%의 생존율을 보임을 확인하였다(도 7).As a result, it was confirmed that when the supernatant of Lactobacillus plantarum WiKim0127 was treated with 10%, the survival rate was 60.2% compared to the control (FIG. 7).
-락토바실러스 플란타룸 WiKim0127 사균체 , 배양액( 발효물 ) 및 파쇄물 제조 - Lactobacillus Plantarum WiKim0127 Production of dead cells , culture ( fermented ) and lysate
락토바실러스 플란타룸 WiKim0127의 소재 활용을 위해 사균체, 배양액(발효물) 및 파쇄물을 제조하였다. To utilize the material of Lactobacillus plantarum WiKim0127, dead cells, culture (fermented) and lysate were prepared.
사균체는 락토바실러스 플란타룸 WiKim0127을 30℃에서 24시간 배양하여 수득한 세포를 121℃에서 15 psi의 가압증기로 15분간 처리하여 제조하였다. 파쇄물은 수득한 세포를 초음파분쇄하여 제조하였다. 배양액은 원심분리를 통해 상등액만을 수득하여 제조하였다(도 8). The dead cells were prepared by treating the cells obtained by culturing Lactobacillus plantarum WiKim0127 at 30° C. for 24 hours at 121° C. with 15 psi of pressurized steam for 15 minutes. The lysate was prepared by sonicating the obtained cells. The culture medium was prepared by obtaining only the supernatant through centrifugation (FIG. 8).
각 사균체, 발효물 및 파쇄물은 동결건조하여 보존하고 농도별로 사용하였다. Each dead cell, fermented product and lysate were freeze-dried and preserved and used by concentration.
-항염 활성 평가 - Anti- inflammatory activity evaluation
RAW 264.7 세포를 96 well에 분주하여 2시간 배양한 후, 락토바실러스 플란타룸 WiKim0127 상등액 및 사균체를 각각 처리하고 1시간 후, 염증 유발 물질인 LPS (Lipopolysaccharide) 1μg/mL을 처리하여 배양하였다. RAW 264.7 cells were dispensed into 96 wells and cultured for 2 hours, Lactobacillus plantarum WiKim0127 supernatant and dead cells were treated, respectively, and 1 hour later, LPS (Lipopolysaccharide) 1 μg/mL, an inflammatory substance, was treated and cultured.
이후, 세포배양 상등액을 회수하여, 그리스 시약(griess reagent)을 이용하여 NO 생성량을 측정하였다. Thereafter, the cell culture supernatant was recovered, and the amount of NO production was measured using a grease reagent.
즉, 세포배양 상등액에 설파닐아미드(sulfanilamide) 용액을 넣고, 상온에서 10분간 반응시킨 후, NED(N-1-napthylethylenediamine dihydrochloride) 용액을 넣고, 상온에서 10분간 반응하여 흡광도(520 nm)를 측정하였다. That is, a sulfanilamide solution was added to the cell culture supernatant, reacted at room temperature for 10 minutes, NED (N-1-napthylethylenediamine dihydrochloride) solution was added, and the absorbance (520 nm) was measured by reacting at room temperature for 10 minutes. did.
NO 생성량은 아질산나트륨(sodium nitrite)을 표준물질로 사용하여 검량선을 작성하였고, 이에 대입하여 NO 생성량을 계산하여 나타내었다. The amount of NO production was calculated using sodium nitrite as a standard material and a calibration curve was prepared, and the amount of NO production was calculated by substituting it.
그 결과, 락토바실러스 플란타룸 WiKim0127 상등액을 20% 농도로 처리한 경우 NO 생성량은 positive control 대비 21.9% 이상의 억제효과를 나타냄을 확인하였다(도 9). 또한 락토바실러스 플란타룸 WiKim0127 사균체를 0.1 mg/mL 농도로 처리한 경우 37.5% 이상의 억제효과를 나타냄을 확인하였다(도 10). As a result, it was confirmed that when the Lactobacillus plantarum WiKim0127 supernatant was treated at a concentration of 20%, the NO production amount exhibited an inhibitory effect of 21.9% or more compared to the positive control (FIG. 9). In addition, it was confirmed that when Lactobacillus plantarum WiKim0127 dead cells were treated at a concentration of 0.1 mg/mL, an inhibitory effect of 37.5% or more was exhibited (FIG. 10).
-대장균 및 살모넬라 타이피뮤리움에 대한 생육 억제 활성 - Growth inhibitory activity against E. coli and Salmonella typhimurium
상기 제조된 본원발명의 락토바실러스 플란타룸 WiKim0127의 상등액을 10배 농축하여 대장균(Escherichia coli) 및 살모넬라 타이피뮤리움(Salmonella typhimurium)에 처리한 결과, 상기 도 11과와 같이 7.6 mm 이상의 생육 억제환을 형성함을 확인하였다(도 11).The supernatant of the Lactobacillus plantarum WiKim0127 of the present invention prepared above was concentrated 10 times to Escherichia (E. coli). coli ) and Salmonella typhimurium ) As a result, it was confirmed that a growth inhibition ring of 7.6 mm or more was formed as shown in FIG. 11 ( FIG. 11 ).
이에 따라 본원발명의 락토바실러스 플란타룸 WiKim0127 균주가 대장균(Escherichia coli) 및 살모넬라 타이피뮤리움(Salmonella typhimurium)에 대해 항균 활성을 나타내고 동시에 이들 균주와 관련된 염증 질환에 대해 효과를 나타냄을 알 수 있다.Accordingly, it can be seen that the Lactobacillus plantarum WiKim0127 strain of the present invention exhibits antibacterial activity against Escherichia coli and Salmonella typhimurium and at the same time exhibits an effect on inflammatory diseases related to these strains.
실시예Example 3: 선별된 3: selected 락토바실러스Lactobacillus 플란타룸Plantarum WiKim0127의WiKim0127's 생화학적 특성 분석 Biochemical characterization
-- 락토바실러스Lactobacillus 플란타룸Plantarum WiKim0127의WiKim0127's 특성 분석 Characterization
본 연구를 통해 확보한 락토바실러스 플란타룸 WiKim0127에 대한 형태적, 생화학적 특성을 분석하였다. Morphological and biochemical characteristics of Lactobacillus plantarum WiKim0127 obtained through this study were analyzed.
분리 균주의 형태 관찰은 24시간 배양하고 crystal violet으로 그람염색한 후 광학현미경을 통해 형태 관찰을 진행하였다. 배양 특성을 분석하기 위해 Aerobic 및 anaerobic 조건에서 배양하여 생장 유무를 확인하였다.The morphology of the isolated strain was observed through an optical microscope after incubation for 24 hours and Gram staining with crystal violet. To analyze the culture characteristics, growth was confirmed by culturing in aerobic and anaerobic conditions.
그 결과, 락토바실러스 플란타룸 WiKim0127은 rod 형태의 그람양성 균주임을 확인하였다. 또한, 산소 유무와 관계없이 증식하는 통성혐기성균임을 확인하였다(표 1).As a result, it was confirmed that Lactobacillus plantarum WiKim0127 was a gram-positive strain in the form of rod. In addition, it was confirmed that facultative anaerobes that proliferate regardless of the presence or absence of oxygen (Table 1).
-유전학적 동정-genetic identification
본 발명의 락토바실러스 플란타룸 WiKim0127 균주의 16S rRNA 유전자 분석을 통한 유전학적 동정을 진행하였다.Genetic identification was performed through 16S rRNA gene analysis of the Lactobacillus plantarum WiKim0127 strain of the present invention.
분석 결과, 99% 이상의 상동성을 가지는 락토바실러스 플란타룸(Lactobacillus plantarum) 균주로 확인되었다(표 2). 즉, 서열번호: 1의 핵산서열을 갖는 것으로 나타났다.As a result of the analysis, it was confirmed as a Lactobacillus plantarum strain having more than 99% homology (Table 2). That is, it was found to have the nucleic acid sequence of SEQ ID NO: 1.
이에, 본 발명의 미생물을 락토바실러스 플란타룸 WiKim0127(Lactobacillus plantarum WiKim0127)으로 명명하였으며, 한국미생물보존센터에 2020년 10월 15일자로 기탁하였다(KFCC11873P).Accordingly, the microorganism of the present invention was named Lactobacillus plantarum WiKim0127 ( Lactobacillus plantarum WiKim0127), and was deposited at the Korea Microbial Conservation Center on October 15, 2020 (KFCC11873P).
<110> KOREA FOOD RESEARCH INSTITUTE <120> LACTOBACILLUS PLANTARUM WIKIM0127 STRAIN DERIVED FROM JEJU PICKLED CABBAGE FOOD AND METHOD FOR PREPARING COMPOSITION USING SAME <130> P21R10C1340 <160> 3 <170> KoPatentIn 3.0 <210> 1 <211> 1505 <212> RNA <213> Lactobacillus plantarum <220> <221> rRNA <222> (1)..(1505) <223> Lactobacillus plantarum WiKim0127 <400> 1 taatacatgc aagtcgaacg aactctggta ttgattggtg cttgcatcat gatttacatt 60 tgagtgagtg gcgaactggt gagtaacacg tgggaaacct gcccagaagc gggggataac 120 acctggaaac agatgctaat accgcataac aacttggacc gcatggtccg agcttgaaag 180 atggcttcgg ctatcacttt tggatggtcc cgcggcgtat tagctagatg gtggggtaac 240 ggctcaccat ggcaatgata cgtagccgac ctgagagggt aatcggccac attgggactg 300 agacacggcc caaactccta cgggaggcag cagtagggaa tcttccacaa tggacgaaag 360 tctgatggag caacgccgcg tgagtgaaga agggtttcgg ctcgtaaaac tctgttgtta 420 aagaagaaca tatctgagag taactgttca ggtattgacg gtatttaacc agaaagccac 480 ggctaactac gtgccagcag ccgcggtaat acgtaggtgg caagcgttgt ccggatttat 540 tgggcgtaaa gcgagcgcag gcggtttttt aagtctgatg tgaaagcctt cggctcaacc 600 gaagaagtgc atcggaaact gggaaacttg agtgcagaag aggacagtgg aactccatgt 660 gtagcggtga aatgcgtaga tatatggaag aacaccagtg gcgaaggcgg ctgtctggtc 720 tgtaactgac gctgaggctc gaaagtatgg gtagcaaaca ggattagata ccctggtagt 780 ccataccgta aacgatgaat gctaagtgtt ggagggtttc cgcccttcag tgctgcagct 840 aacgcattaa gcattccgcc tggggagtac ggccgcaagg ctgaaactca aaggaattga 900 cgggggcccg cacaagcggt ggagcatgtg gtttaattcg aagctacgcg aagaacctta 960 ccaggtcttg acatactatg caaatctaag agattagacg ttcccttcgg ggacatggat 1020 acaggtggtg catggttgtc gtcagctcgt gtcgtgagat gttgggttaa gtcccgcaac 1080 gagcgcaacc cttattatca gttgccagca ttaagttggg cactctggtg agactgccgg 1140 tgacaaaccg gaggaaggtg gggatgacgt caaatcatca tgccccttat gacctgggct 1200 acacacgtgc tacaatggat ggtacaacga gttgcgaact cgcgagagta agctaatctc 1260 ttaaagccat tctcagttcg gattgtaggc tgcaactcgc ctacatgaag tcggaatcgc 1320 tagtaatcgc ggatcagcat gccgcggtga atacgttccc gggccttgta cacaccgccc 1380 gtcacaccat gagagtttgt aacacccaaa gtcggtgggg taacctttta ggaaccagcc 1440 gcctaaggtg ggacagatga ttagggtgaa gtcgtaacaa ggtagccgta ggagaacctg 1500 cggct 1505 <210> 2 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> 27F Primer <220> <221> primer_bind <222> (1)..(20) <223> Forward Primer <400> 2 agagtttgat cctggctcag 20 <210> 3 <211> 19 <212> DNA <213> Artificial Sequence <220> <223> 1492R Primer <220> <221> primer_bind <222> (1)..(19) <223> Reverse Primer <400> 3 ggctaccttg ttacgactt 19 <110> KOREA FOOD RESEARCH INSTITUTE <120> LACTOBACILLUS PLANTARUM WIKIM0127 STRAIN DERIVED FROM JEJU PICKLED CABBAGE FOOD AND METHOD FOR PREPARING COMPOSITION USING SAME <130> P21R10C1340 <160> 3 <170> KoPatentIn 3.0 <210> 1 <211> 1505 <212> RNA <213> Lactobacillus plantarum <220> <221> rRNA <222> (1)..(1505) <223> Lactobacillus plantarum WiKim0127 <400> 1 taatacatgc aagtcgaacg aactctggta ttgattggtg cttgcatcat gatttacatt 60 tgagtgagtg gcgaactggt gagtaacacg tgggaaacct gcccagaagc gggggataac 120 acctggaaac agatgctaat accgcataac aacttggacc gcatggtccg agcttgaaag 180 atggcttcgg ctatcacttt tggatggtcc cgcggcgtat tagctagatg gtggggtaac 240 ggctcaccat ggcaatgata cgtagccgac ctgagagggt aatcggccac attgggactg 300 agacacggcc caaactccta cgggaggcag cagtagggaa tcttccacaa tggacgaaag 360 tctgatggag caacgccgcg tgagtgaaga agggtttcgg ctcgtaaaac tctgttgtta 420 aagaagaaca tatctgagag taactgttca ggtattgacg gtatttaacc agaaagccac 480 ggctaactac gtgccagcag ccgcggtaat acgtaggtgg caagcgttgt ccggatttat 540 tgggcgtaaa gcgagcgcag gcggtttttt aagtctgatg tgaaagcctt cggctcaacc 600 gaagaagtgc atcggaaact gggaaacttg agtgcagaag aggacagtgg aactccatgt 660 gtagcggtga aatgcgtaga tatatggaag aacaccagtg gcgaaggcgg ctgtctggtc 720 tgtaactgac gctgaggctc gaaagtatgg gtagcaaaca ggattagata ccctggtagt 780 ccataccgta aacgatgaat gctaagtgtt ggagggtttc cgcccttcag tgctgcagct 840 aacgcattaa gcattccgcc tggggagtac ggccgcaagg ctgaaactca aaggaattga 900 cgggggcccg cacaagcggt ggagcatgtg gtttaattcg aagctacgcg aagaacctta 960 ccaggtcttg acatactatg caaatctaag agattagacg ttcccttcgg ggacatggat 1020 acaggtggtg catggttgtc gtcagctcgt gtcgtgagat gttgggttaa gtcccgcaac 1080 gagcgcaacc cttattatca gttgccagca ttaagttggg cactctggtg agactgccgg 1140 tgacaaaccg gaggaaggtg gggatgacgt caaatcatca tgccccttat gacctgggct 1200 acacacgtgc tacaatggat ggtacaacga gttgcgaact cgcgagagta agctaatctc 1260 ttaaagccat tctcagttcg gattgtaggc tgcaactcgc ctacatgaag tcggaatcgc 1320 tagtaatcgc ggatcagcat gccgcggtga atacgttccc gggccttgta cacaccgccc 1380 gtcacaccat gagagtttgt aacacccaaa gtcggtgggg taacctttta ggaaccagcc 1440 gcctaaggtg ggacagatga ttagggtgaa gtcgtaacaa ggtagccgta ggagaacctg 1500 cggct 1505 <210> 2 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> 27F Primer <220> <221> primer_bind <222> (1)..(20) <223> Forward Primer <400> 2 agagtttgat cctggctcag 20 <210> 3 <211> 19 <212> DNA <213> Artificial Sequence <220> <223> 1492R Primer <220> <221> primer_bind <222> (1)..(19) <223> Reverse Primer <400> 3 ggctaccttg ttacgactt 19
Claims (10)
상기 염증 질환은 식중독, 장염 및 패혈증으로 이루어진 군으로부터 선택되는 하나 이상의 질환인, 염증 질환의 예방 또는 치료용 약학적 조성물.According to claim 1,
The inflammatory disease is one or more diseases selected from the group consisting of food poisoning, enteritis and sepsis, a pharmaceutical composition for preventing or treating inflammatory diseases.
상기 외용제는 연고, 패취, 겔, 크림 또는 분무제 제형인 피부 외용제.5. The method of claim 4,
The external preparation is an ointment, patch, gel, cream or spray formulation.
상기 화장료 조성물은 화장수, 에센스, 로션, 크림, 앰플, 팩, 젤, 파우더, 파운데이션, 비누 또는 세정제의 제형인 피부 항균용 화장료 조성물.7. The method of claim 6,
The cosmetic composition is a cosmetic composition for antibacterial skin in the formulation of a lotion, essence, lotion, cream, ampoule, pack, gel, powder, foundation, soap or detergent.
상기 화장료 조성물은 화장수, 에센스, 로션, 크림, 앰플, 팩, 젤, 파우더, 파운데이션, 비누 또는 세정제의 제형인 피부 항염용 화장료 조성물.9. The method of claim 8,
The cosmetic composition is a cosmetic composition for skin anti-inflammatory in the formulation of a lotion, essence, lotion, cream, ampoule, pack, gel, powder, foundation, soap or detergent.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020210129717A KR102457366B1 (en) | 2021-09-30 | 2021-09-30 | Lactobacillus plantarum wikim0127 strain derived from jeju pickled cabbage food and method for preparing composition using same |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020210129717A KR102457366B1 (en) | 2021-09-30 | 2021-09-30 | Lactobacillus plantarum wikim0127 strain derived from jeju pickled cabbage food and method for preparing composition using same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR102457366B1 true KR102457366B1 (en) | 2022-10-21 |
Family
ID=83805341
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020210129717A KR102457366B1 (en) | 2021-09-30 | 2021-09-30 | Lactobacillus plantarum wikim0127 strain derived from jeju pickled cabbage food and method for preparing composition using same |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR102457366B1 (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6235138B2 (en) * | 2013-07-18 | 2017-11-22 | 株式会社アミノアップ化学 | Composition having prebiotic effect |
| KR20190056177A (en) * | 2017-11-16 | 2019-05-24 | 씨제이제일제당 (주) | Cosmetic comoposition for antibacterial comprising Lactobacillus plantarum culture |
| KR102254751B1 (en) * | 2020-01-09 | 2021-05-24 | 한국식품연구원 | New Lactobacillus plantarum WiKim83 and use thereof |
-
2021
- 2021-09-30 KR KR1020210129717A patent/KR102457366B1/en active IP Right Grant
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6235138B2 (en) * | 2013-07-18 | 2017-11-22 | 株式会社アミノアップ化学 | Composition having prebiotic effect |
| KR20190056177A (en) * | 2017-11-16 | 2019-05-24 | 씨제이제일제당 (주) | Cosmetic comoposition for antibacterial comprising Lactobacillus plantarum culture |
| KR102254751B1 (en) * | 2020-01-09 | 2021-05-24 | 한국식품연구원 | New Lactobacillus plantarum WiKim83 and use thereof |
Non-Patent Citations (2)
| Title |
|---|
| Andrea Counti et al., Contact Dermatitis, 1997, 37: 35-36; Edwin et al., Toxicology and Applied Pharmacology, 1998, 153: 12-19 |
| EI-shenawy et al., J. Food Protec. 1989, 52(11): 771-778; Bizri et al ., J. Food Science, 1994, 59(1):130-135 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102070143B1 (en) | Lactobacillus plantarum WiKim0060 having skin whitening and skin moisturizing activities and composition for comprising the same | |
| US9080219B2 (en) | Bacillus amyloliquefaciens K317 for suppressing the growth of antibiotics-resistant pathogenic microorganism or enteropathogenic microorganism | |
| JP2019069963A (en) | Novel bacillus velezensis cjbv and antimicrobial composition containing the same | |
| KR102562507B1 (en) | Novel lactobacillus paracasei subsp. tolerans wikim0148 with potent anti-inflammatory activity and uses thereof | |
| KR102123505B1 (en) | Lactobacillus sakei WIKIM0109 having anti-arthritis activity and composition for comprising the same | |
| KR20190051771A (en) | Lactobacillus plantarum WiKim0062 having anti-obesity activity and composition comprising the same | |
| KR101838281B1 (en) | Lactobacillus curvatus WIKIM53 having anti-allergic disease activity and composition for comprising the same | |
| KR20220092787A (en) | A novel Lactobacillus paracasei strain and uses thereof | |
| KR102313770B1 (en) | LACTOBACILLUS PLANTARUM WiKim0127 STRAIN DERIVED FROM JEJU PICKLED CABBAGE FOOD AND METHOD FOR PREPARING COMPOSITION USING SAME | |
| KR101394322B1 (en) | New Bacillus subtilis BCNU 9169 and probiotics composition comprising the same | |
| KR102052047B1 (en) | Pediococcus pentosaceus having antibacterial activity and uses thereof | |
| KR101757785B1 (en) | Leuconostoc lactis WIKIM48 having high productivity of 2-hydroxyisocaproic acid and composition for comprising the same | |
| KR101825837B1 (en) | Novel Lactobacillus plantarum Ln4 strain and compositions for the prevention and treatment of diabetes or insulin resistance syndrome containing the same | |
| KR20160110744A (en) | Leuconostoc lactis EFEL005 Strain Having Probiotic Activities and the Use of Thereof | |
| KR102178350B1 (en) | Bacillus safensis strain with antibiotic activity and antibiotic use thereof | |
| KR101992331B1 (en) | Leuconostoc citreum WiKim0059 having skin whitening and skin moisturizing activities and composition for comprising the same | |
| KR101836365B1 (en) | Kimchi seasoning containing Leuconostoc mesenteroides WiKim32 and kimchi prepared by using the same | |
| KR102313769B1 (en) | Lactobacillus plantarum wikim0126 strain derived from jeju pickled brussels sprout food and method for preparing composition using same | |
| KR102463809B1 (en) | Lactobacillus paracasei wikim0110 having antibacterial activity against clostridioides difficile and composition comprising the same | |
| KR20080087230A (en) | Lactic acid bacteria separated from kimchi and uses thereof | |
| KR102457366B1 (en) | Lactobacillus plantarum wikim0127 strain derived from jeju pickled cabbage food and method for preparing composition using same | |
| KR102350473B1 (en) | Composition for Improving Bowel Function or Increasing Intestinal Microbes | |
| KR102457367B1 (en) | Lactobacillus plantarum wikim0126 strain derived from jeju pickled brussels sprout food and method for preparing composition using same | |
| KR101838280B1 (en) | Leuconostoc citreum WIKIM56 having anti-arthritis activity and composition for comprising the same | |
| KR20110112229A (en) | Pediococcus acidilactici wrl-1 and use of the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant |